Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants

Clinical Pharmacokinetics

Volumn 38, Issue 4, 2000, Pages 355-365

  Wilbur, Kerry ^a   Ensom, Mary H H ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^c Children's and Women's H ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 3A; DESOGESTREL; DIRITHROMYCIN; ESTROGEN; ETHINYLESTRADIOL; FELBAMATE; GABAPENTIN; GESTAGEN; LAMOTRIGINE; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; SEX HORMONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AFFECTIVE NEUROSIS; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; HUMAN; LENNOX GASTAUT SYNDROME; MENSTRUAL IRREGULARITY; META ANALYSIS; MIGRAINE; OVARY FOLLICLE MATURATION; OVULATION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE;

EID: 0034095323     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038040-00004     Document Type: Review

References (83)

1. 1. Zachariasen RD. Loss of oral contraceptive efficacy by concurrent antibiotic administration. Women's Health 1994; 22: 17-6
2. 2. Canadian Broadcasting Company. The nature of things, controversial and dramatic look at the pill (archive 11 March, 1999) [documentary abstract online]. Available from: URL: http://www.tv.cbc.ca/nature_of_things/ [Accessed 1999 Mar 13]
3. 3. Neinstein L. Contraception in women with special medical needs. Compr Ther 1998; 24: 229-50
4. 4. Morris S. Drug interaction between phenytoin and oral contraceptives. Drug Intell Clin Pharm 1984; 18: 135-6
5. 5. Kenyon IE. Unplanned pregnancy in an epileptic. BMJ 1972; 1: 686-7
6. 6. Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 592-6
7. 7. Coulan CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20: 519-26
8. 8. Janz D, Schmidt D. Antiepileptic drugs and failure of oral contraceptives [letter]. Lancet 1974; I: 1113
9. 9. Crawford P, Chadwick D, Cleveland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33: 23-9
10. 10. Shenfield GM. Oral contraceptives - are drug interactions of clinical significance? Drug Saf 1993; 9: 21-37
11. 11. Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49 Suppl. 5: 31-8S
12. 12. D'Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986; 20: 353-62
13. 13. Baciewicz AM. Oral contraceptive drug interactions. Ther Drug Monit 1985; 7: 26-35
14. 14. Fraser IS, Jansen RPS. Why do inadvertent pregnancies occur in oral contraceptive users? Contraception 1983; 27: 531-5
15. 15. Back DJ, Breckenridge AM, Crawford FE, et al. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 1981; 21 (1): 46-61
16. 16. Orme MLE, Back DJ. Drug interactions with oral contraceptive steroids. Pharmacy Int 1980; 1: 38-41
17. 17. Robertson YR, Johnson ES. Interactions between oral contraceptives and other drugs - a review. Curr Med Res Opin 1976; 3: 647-58
18. 18. Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472-84
19. 19. Back DJ, Grimmer SFM, Orme ML, et al. Evaluation Committee on Safety of Medicines yellow card reports on oral contraceptives - drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527-32
20. 20. Back DJ, Breckendridge AM, Crawford FE. An investigation of the pharmacokinetics of ethinylestradiol in women using radioimmunoassay. Contraception 1979; 20: 263-73
21. 21. Bolt WH, Kappus H, Bolt HM. Ring A oxidation of 17α-ethinylestradiol in man [abstract]. Horm Metab Res 1974; 6: 432
22. 22. Orme M, Back DJ. Oral contraceptive steroids - pharmacological issues of interest to the prescribing physician. Adv Contracept 1991; 7: 325-31
23. 23. Fotherby K, Akpoviroro JO, Abdel-Rahman HA, et al. Pharmacokinetics of ethanyl estradiol in women from different populations. Contraception 1981; 23: 489-96
24. 24. Timm Wagner L, Kenreigh CA. Choosing oral contraceptives. Am Druggist 1999; 216: 64-71
25. 25. Kaplan B. Desogetrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995; 29: 736-42
26. 26. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986; 33: 559-65
27. 27. Oldlind V, Olsson SE. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception 1986; 33: 257-61
28. 28. Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 11: 533-9
29. 29. Tomson T, Svensson J, Hilton-Brown P. Relationship of inter-individual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 1989; 11: 533-9
30. 30. Patsalos PN, Duncan JS, Shorvon SD. Effect of removal of individual AED on antipyrine kinetics in patients taking polytherapy. Br J Clin Pharmacol 1988; 26: 253-9
31. 31. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-58
32. 32. Wright SA, Stevens JC. The human hepatic cytochromes 450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21
33. 33. Levy RH. Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl. 5: S8-13
34. 34. Backstrom T, Sodergard R. The influence of antiepileptic drugs on steroid plasma levels and binding during the menstrual cycle [abstract]. Acta Endocrinol 1977; 85 Suppl. 212: 42
35. 35. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47
36. 36. Wermeling DP, Chandler MHH, Sides GD, et al. Dithromycin increases ethinyl estradiol clearance without allowing ovulation. Obstet Gynecol 1995; 86: 78-84
37. 37. Wooley DE, Timeras PS. Gonad brain relationship, effect of female sex hormone on electroshock convulsion in rat. Endocrinology 1962; 70: 196-209
38. 38. Logothetis J, Harner R. Electrocorticol activation by estrogens. Arch Neruol 1960; 3: 290-7
39. 39. Gevorkyan ES, Nazaryan KB, Kostanyan AA. Modifying effect of estradiol and progesterone on epileptic activity of the rat brain. Neurosci Behav Physiol 1989; 19: 412-5
40. 40. Espir M, Walker Me, Lawson JP. Epilepsy and oral contraception. BMJ 1969; 1: 294-5
41. 41. Toivakka E. Oral contraception in epileptics [abstract]. Arzneimittelforschung 1967; 17: 1085
42. 42. Diamond MP, Greene JW, Thompson JM, et al. Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 1985; 31: 623-32
43. 43. Porter RJ, Cereghino JJ, Gladding GD, et al. Antiepileptic drug development program. Cleve Clin Q 1984; 51: 293-505
44. 44. Jensen PK. Felbamate in the treatment of refractory partial-on-set seizures. Epilepsia 1993; 34 Suppl.: S25-9
45. 45. Felbamate Study Group In Lennox-Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29-33
46. 46. Graves NM, Holmes GB, Fuerst RH, et al. Effect of felbamate on phenytoin and carbamazepine concentrations. Epilepsia 1989; 30: 225-9
47. 14C-felbamate in healthy men. Epilepsia 1990; 31 Suppl.: 21-2
48. 48. Saano V, Banfield CR, Reidenberg P. et al. Effects of felbamate on the pharmacokinetics of low-dose combination oral contraceptive. Clin Pharmacol Ther 1995; 58: 523-31
49. 49. Klosterskov Jensen P, Saano V, Haring P, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149-52
50. 50. Eldon MA, Underwood BA, Randinitis EJ, et al. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 1998; 50: 1146-8
51. 51. Hengy H, Kolle EU. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and precolumn labeling for ultraviolet detection. J Chromatogr 1985; 341: 473-88
52. 52. Leppik IE. Role of new and established antiepileptic drugs. Epilepsia 1998; 37 Suppl. 5: 2-6
53. 53. Matsuo F. Lamotrigine. Epilepsia 1999; 51 Suppl. 5: 30-6
54. 54. Holdich T, Whiteman P, Orme M, et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill [abstract]. Epilepsia 1991; 32 Suppl.: 96
55. 55. Wagner J, Schmid K. Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine. Xenobiotica 1987; 17: 951-6
56. 56. Larkin JG, McKee PJ, Forrest G, et al Evidence of lack of auto and heteroinduction with the novel anticonvulsant oxcarbazepine in healthy volunteers. Br J Clin Pharmacol 1991; 31: 165-71
57. 57. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependant enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990; 39: 187-8
58. 58. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-7
59. 59. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995; 36 Suppl. 6: S7-9
60. 60. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994; 4: 141-50
61. 61. Herranz JL. Tiagabine - recent findings and recommendations for dosage. Rev Neurol 1998; 27: 101-3
62. 62. So EI, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221-6
63. 63. Sachdeo RC. Topiramate - clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335-46
64. 64. Glauser TA. Topiramate. Epilepsia 1999; 40 Suppl. 5: S70-80
65. 65. Levy RH, Bishop F, Streeter AJ, et al. Explanation and prediction of drug interactions with topiramate using CYP450 inhibition spectrum. Epilepsia 1995; 36 Suppl. 4: 47-51
66. 66. Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38: 317-23
67. 67. Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other antiepileptics with oral contraceptive steroid therapy. Contraception 1980; 22: 495-503
68. 68. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926
69. 69. French JA. Vigabatrin. Epilepsia 1999; 40 Suppl. 5: 11-6
70. 70. Vigabatrin clinical investigator brochure. Strasbourg: Merrell-Dow Research Institute, 1979
71. 71. Perucca E. The clinical pharmacology of new antiepileptic drugs. Pharmacol Res 1993; 28: 89-106
72. 72. Gotti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36: 603-6
73. 73. Rimmer Em, Richens A. Interaction between vigahatrin and phenytoin. Br J Clin Pharmacol 1989; 27: 275-335
74. 74. Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicentre single blind study and long term follow-up. Neurology 1987; 37: 184-9
75. 75. Bartoli A, Gatti G, Cipolla N, et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997; 38 (6): 702-7
76. 76. Leppik EL, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14: 165-73
77. 77. Nakasa H, Komiya M, Ohmori S, et al. Characterization of human liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos 1993; 21: 777-81
78. 78. Nakasa H, Nakamura H, Ono S, et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol 1998; 54: 177-83
79. 79. Sonnen AEH. Oxcarbazepine and oral contraceptives [abstract]. Acta Neurol Scand 1990; 82 Suppl. 133: 37
80. 80. Hatcher RA, Stewart R, Trussel J, et al, editors. Contraceptive technology. 15th ed. New York (NY): Irvington Publishers, 1990-1992: 134
81. 81. Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 1987; 28: 97-106
82. 82. Elwes RDC, Johnson AL, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944-7
83. 83. Krauss GL, Brandt J, Campbell M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 1996; 40: 1534-9